Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Interest Expense : $-0.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lixte Biotechnology Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lixte Biotechnology Holdings's interest expense for the three months ended in Mar. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lixte Biotechnology Holdings's Operating Income for the three months ended in Mar. 2024 was $ -0.97 Mil. Lixte Biotechnology Holdings's Interest Expense for the three months ended in Mar. 2024 was $ -0.01 Mil. Lixte Biotechnology Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lixte Biotechnology Holdings Interest Expense Historical Data

The historical data trend for Lixte Biotechnology Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Interest Expense Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.02

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-0.01	-0.01

Lixte Biotechnology Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Lixte Biotechnology Holdings (NAS:LIXTW) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lixte Biotechnology Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.97 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

Lixte Biotechnology Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Lixte Biotechnology Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXTW) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.